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Simply stated, clinical response to an immunotherapy is
proportional to the product of three quantities: the total
number of tumor-infiltrating lymphocytes (TILs), the
proportion of tumor cells that can be recognized by
these TILs, and the cytotoxic efficacy of TILs directed
against tumor cells. Recent clinical responses to Ipilimu-
mab illustrate that TILs recognize tumor cells and that
modifying immune checkpoints can increase the total
number of T lymphocytes. Yet until we identify which of
the many putative or potentially undiscovered local bio-
chemical mechanisms limit the cytotoxic efficacy of TILs,
the subset of patients that respond to these immune
checkpoint modulators will be limited, as is the current
state for Ipilimumab. To address this problem, we have
developed a phenotypic screening workflow to identify
local mechanisms that malignant cells use to suppress
anti-tumor immunity. Specifically we have focused on
identifying tumor-derived cues that locally suppress lym-
phocyte response to Interleukin-12, a key link between
innate and adaptive immunity. By integrating high con-
tent assays, proteomics, and in silico methods, we identi-
fied tumor-derived Wnt-inducible signaling protein-1
(WISP1) as a paracrine suppressor of T cell response to
IL-12 in vitro [1,2]. In patients with invasive breast can-
cer, we found that WISP1 is up-regulated in essentially
all tumor samples from patients with invasive breast can-
cer [3]. While a type 1 immune response was correlated
with improved survival in these patients, we also found
that the expression of WISP1 correlated with a shift in
immune polarization from a type 1 to a type 2 response.
This observation is consistent with WISP1 as a paracrine
regulator of immune response to IL12. Overall, this
example serves to illustrate how a quantitative systems
approach can be used to inform therapeutic strategies
that enhance anti-tumor immunity and overcome local
mechanisms for immunosuppression.
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